Safety Study of Syntropin (Human Growth Hormone) for the Treatment of Growth Hormone Deficiency

Growth Hormone Deficiency Clinical Trial

Official title:

An Open-Label Study of the Pharmacokinetics and Pharmacodynamics of Syntropin (a Human Growth Hormone) in Growth Hormone-Suppressed Healthy Volunteers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00489294
• Other study ID #: SYN-05-001
• Status: Completed
• Phase: Phase 1
• First received: June 19, 2007
• Last updated: March 9, 2012
• Start date: August 2004
• Est. completion date: June 2005

Study information

• Verified date: March 2012
• Source: Phage Pharmaceuticals, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the pharmacokinetics of Syntropin (a human growth hormone) and to determine the serum concentration of IGF-1 after Syntropin injection.

Description:

Syntropin will be administered by subcutaneous injection. Eligible patients will receive a subcutaneous injection of octreodite (to suppress endogenous growth hormone secretion) 12 hours before, immediately prior to, and 12 hours after the scheduled injection of growth hormone.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: June 2005
• Est. primary completion date: June 2005
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Male and female subjects between the ages of 18 and 45 years (inclusive).

• Written informed consent to participate in the study.

• Body mass index between 19 and 31 kg/m².

• Female subjects of childbearing potential, defined as not surgically sterile or at least 2 years postmenopausal, must agree to use one of the following forms of contraception from 3 months prior through 7 days following the last dose of study drug: hormonal (oral, transdermal, implant, or injection), barrier (condom, diaphragm with spermicide), IUD, or vasectomized partner (6 months minimum). Subjects must have used the same method for at least 3 months prior to starting the study.

• No clinically significant abnormal findings on the physical examination, medical history, electrocardiogram, or clinical laboratory results during screening.

• Screening growth hormone and insulin-like growth factor I (IGF-I) within normal limits.

Exclusion Criteria

• A history of clinically significant gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric, or cardiovascular disease or any other condition which, in the opinion of the Principle Investigator, would jeopardize the safety of the subject or impact the validity of the study results.

• A history of allergic or adverse responses to growth hormone, glycerin, or metacresol, or any comparable or similar product.

• Subjects who (for whatever reason) have been on an abnormal diet during the four weeks preceding the study.

• Subjects who donated blood within 30 days or plasma within 14 days of the first study dosing.

• Participation in a clinical trial within 30 days prior to study initiation.

• Use of any over-the-counter (OTC) medication, including vitamins, within 7 days prior to or during the study.

• Use of any prescription medication within 14 days prior to or during the study, with the exception of hormonal contraceptives for women of childbearing potential.

• Treatment with any known enzyme altering drugs such as barbiturates, phenothiazines, cimetidine, carbamazepine, etc., within 30 days prior to or during the study.

• Smoking or use of tobacco products within 6 months prior to or during the study.

• Female subjects who are trying to conceive, are pregnant, or are lactating.

• Positive serum pregnancy test at screening or urine pregnancy test prior to each drug administration for all women regardless of childbearing potential.

• Positive blood screen for HIV, Hepatitis B surface antigen (HbSAg), or Hepatitis C, or a positive urine screen for alcohol or drugs of abuse.

Study Design

Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Dwarfism, Pituitary
• Endocrine System Diseases
• Growth Hormone Deficiency

Intervention

Drug:
• Syntropin

Locations

Country	Name	City	State
United States	Novum Pharmaceutical Research Services	Houston	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Phage Pharmaceuticals, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	pharmacokinetics
Secondary	serum concentrations of insulin-like growth factor-1 (IGF-1)